NTLA

#2071
Intellia Therapeutics, Inc
14.8600 USD
+4.21%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
14.7400
14.8800
년간 변동
7.9500
17.0900
일일 변동
+4.21%
월간 변동
+13.26%
6달 변화
+8.31%
년간 변동율
+8.31%
이전 종가
14.2600
Open
14.7650
Bid
Ask
Low
14.7400
High
14.8800
양
62
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 1.7555 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.36
Price to sales ratio
14.4

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

뉴스